Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.77 |
| ▸ | CA2 | P00918 | 7/20 | 0.77 |
| ▸ | CA12 | O43570 | 4/20 | 0.77 |
| ▸ | CA9 | Q16790 | 4/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.47 |
| ▸ | PDE4A | P27815 | 9/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522840 | 0.87 | CA1 (1.00) | CA1CA2CA12CA9CA4 | |
| SCHEMBL594681 | 0.87 | CA1 (1.00) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2529948 | 0.84 | PDE4B (0.67) | CA1CA2CA12CA9PDE3A | |
| SCHEMBL26425598 | 0.81 | CA1 (0.56) | CA1CA2CA12CA9PDE3A | |
| SCHEMBL29885125 | 0.77 | MEN1 (0.60) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL2529971 | 0.76 | PDE4B (0.55) | CA1CA2CA12CA9PDE3A | |
| SCHEMBL2281440 | 0.76 | CA1 (0.72) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1135237 | 0.76 | CA1 (0.72) | CA1CA2CA12CA9PDE4B | |
| SCHEMBL2434037 | 0.75 | CA1 (0.73) | CA1CA2CA12CA9CA4 | |
| SCHEMBL16101886 | 0.73 | CA1 (0.57) | CA1CA2CA12CA9PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2016138352-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| EP-2673281-B1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2673281-B1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-8933018-B2 | Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933018-B2 | Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2673281-A1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012109164-A1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CA1 4879/4885CA2 4600/4885CA12 4833/4885 |
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CA1 4879/4885CA2 4600/4885CA12 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.